Summary
U.S. Food and Drug Administration announced a Digital Health Advisory Committee meeting focused on generative‑AI digital mental‑health devices, opening a public docket and inviting expert input on benefits, risks, evidence, and oversight priorities.
Healthcare Implications
Signals near‑term policy attention; developers and clinicians can submit comments, preview evidence expectations, and anticipate future guidance affecting evaluation and post‑market monitoring of mental‑health AI tools.